Advertisement

Inflammatory Myopathies

  • Ira N. Targoff
  • Chester V. Oddis
  • Paul H. Plotz
  • Frederick W. Miller
  • Mark Gourley

Abstract

The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized by varied patterns of inflammation within striated muscle. The major disease categories among the IIM are der-matomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), myositis associated with connective tissue diseases, and myositis associated with malignancy. The skin, joints, lungs, heart, and gastrointestinal tract are also involved in different forms of these disorders. Muscle weakness that is proximal, symmetrical, and painless is a hallmark feature of the inflammatory myopathies. Patients with IBM are also prone to distal, asymmetric muscle involvement. Measurement of serum concentrations of muscle enzymes, skin and muscle biopsy, electromyography, and magnetic resonance imaging can assist in the diagnosis. Testing for serum autoantibodies is helpful both in diagnosis and in predicting the clinical phenotype and response to therapy. A minority of patients with DM and PM have myositis that is associated with an underlying malignancy. The risk is greatest for middle-aged to elderly patients with DM. Approximately 15% of DM patients have malignancy-associated disease. Most malignancies present within 1 year before or after the diagnosis of inflammatory myopathy.

Keywords

Creatine Kinase Interstitial Lung Disease Serum Creatine Kinase Inclusion Body Myositis Inflammatory Myopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alexanderson H, Dastalmachi M, Esbjornsson-Liljedahl M, et al Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Care Res 2007; 57:768.CrossRefGoogle Scholar
  2. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2 N. Engl J Med 1975; 292:344–3447,403–407PubMedCrossRefGoogle Scholar
  3. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087–1095.Google Scholar
  4. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet 2001; 357:85–86PubMedCrossRefGoogle Scholar
  5. Chinoy H, Fertig N, Oddis C V, et al The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345–1349PubMedCrossRefGoogle Scholar
  6. Dimitri D, Andre C, Roucoules J, et al Myopathy associated with anti-signal recognition peptide antibodies: Alinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35:389–395PubMedCrossRefGoogle Scholar
  7. Dion E, Cherin P, Payan C, et al Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyosi-tis. J Rheumatol. 2002; 29:1897PubMedGoogle Scholar
  8. Erlacher P, Lercher A, Falkensammer J, et al Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyosi-tis or dermatomyositis. Clin Chim Acta 2001; 306:27–33PubMedCrossRefGoogle Scholar
  9. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoan-tibodies against aminoacyl- tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26:459–467PubMedCrossRefGoogle Scholar
  10. Gerami P, Schope JM, McDonald L, et al A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597–613PubMedCrossRefGoogle Scholar
  11. Hengstman GJ, van Brenk L, Vree Egberts WT, et al High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005; 252:534–537PubMedCrossRefGoogle Scholar
  12. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635–1638PubMedCrossRefGoogle Scholar
  13. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in der-matomyositis and polymyositis: a population-based study. Lancet 2001; 357:96–100PubMedCrossRefGoogle Scholar
  14. Hirakata M, Suwa A, Takada T, et al Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007; 56:1295–1303PubMedCrossRefGoogle Scholar
  15. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol 1999; 455:85–92PubMedCrossRefGoogle Scholar
  16. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987; 30: 213–217PubMedCrossRefGoogle Scholar
  17. Kaji K, Fujimoto M, Hasegawa M, et al Identification of a novel autoanti-body reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: An association with malignancy. Rheumatology 2007; 6:25–28PubMedCrossRefGoogle Scholar
  18. Kao AH, Lacomis D, Lucas M, et al Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflam-matory myopathy. 2004; Arthritis Rheum. 50:209–215PubMedCrossRefGoogle Scholar
  19. Koenig M, Fritzler MJ, Targoff IN, et al Heterogeneity of autoantibod-ies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes. Arthritis Res Therapy 2007; 9:R78CrossRefGoogle Scholar
  20. Love LA, Leff RL, Fraser DD, et al A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoanti-bodies define useful homogeneous patient groups. Medicine 1991; 70:360–374PubMedCrossRefGoogle Scholar
  21. Miller T, Al Lozi MT, Lopate G, et al Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; n73–420 428PubMedCrossRefGoogle Scholar
  22. Oddis C V, Medsger TA Jr., Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomy-ositis. Arthritis Rheum 1990; 33:1640–1645PubMedCrossRefGoogle Scholar
  23. Oddis CV, Okano Y, Rudert WA, et al Serum autoantibody to the nucle-olar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992; 35:1211–1217PubMedCrossRefGoogle Scholar
  24. Oh TH, Brumfield KA, Hoskin TL, et al Dysphagia in inflammatory myopathy: Clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007; 82: 441–447PubMedCrossRefGoogle Scholar
  25. Quain RD, Teal V, Taylor L, et al Number, characteristics, & classification of dermatomyositis patients seen by dermatology & rheumatology at a tertiary medical center. J Am Acad Dermatol 2007; 57:937–943CrossRefGoogle Scholar
  26. Rider LG, Giannini EH, Brunner HI, et al International consensus on preliminary definitions of improvement in adult and juvenile myosi-tis. Arthritis Rheum 2004; 50:2281–2290PubMedCrossRefGoogle Scholar
  27. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibod-ies. Rheumatology 2007; 46:842–845PubMedCrossRefGoogle Scholar
  28. Schmidt WA, Wetzel W, Friedlander R, et al Clinical and serological aspects of patients with anti-Jo-1 antibodies–an evolving spectrum of disease manifestations. Clin Rheumatol 2000; 19:371–377PubMedCrossRefGoogle Scholar
  29. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88: 241–251PubMedCrossRefGoogle Scholar
  30. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91:2556–2564PubMedCrossRefGoogle Scholar
  31. Targoff IN, Mamyrova G, Trieu EP, et al A novel autoantibody to a 155-kd protein is associated with dermatomyositis Arthritis Rheum 2006; 54:3682–3689PubMedCrossRefGoogle Scholar
  32. Tillie-Leblond I, Wislez M, Valeyre D, et al Interstitial lung disease and anti-Jo-1 antibodies: Difference between acute and gradual onset. Thorax 2008; 63:53–59PubMedCrossRefGoogle Scholar
  33. Villalba L, Hicks J, Adams E, et al Treatment of refractory myositis: A randomized crossover study of two new cytoxic regimens. Arthritis Rheum 1998; 41:392–399PubMedCrossRefGoogle Scholar
  34. Whitcomb ME, Schwarz MI, Tormey DC. Methotrexate pneumonitis: Case report and review of the literature. Thorax 1972; 27(5):636–639PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Ira N. Targoff
    • 1
  • Chester V. Oddis
    • 2
  • Paul H. Plotz
    • 3
  • Frederick W. Miller
    • 4
  • Mark Gourley
    • 5
  1. 1.Oklahoma Medical Research Foundation Arthritis & ImmunologyOklahomaUSA
  2. 2.University of Pittsburgh Medicine/RheumatologyBST PittsburghPennsylvania
  3. 3.Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institutes of HealthRockville PikeUSA
  4. 4.Environmental Autoimmunity Group National Institutes of Health / NIEHS BuildingRockville Pike MSC 1301Bethesda
  5. 5.National Institute of Arthritis and Musculoskeletal DiseasesNational Institutes of HealthMaryland

Personalised recommendations